Medix Biochemica’s growth in China proves that, even in low-cost countries, businesses can be competitive and achieve success through quality.
Medix Biochemica produces bioreagents for the diagnostics industry and rapid tests for the use of healthcare professionals. The rapid growth of exports to China has been a major contributing factor in the growth experienced by the company in recent years. As a result, Medix Biochemica has opened a joint office together with its partner in Shanghai.
According to CEO Ismo Råman, the Chinese health care system is currently undergoing a major reform. The state is investing billions in the health care sector. This reform cannot be completed successfully without Western know-how, which is needed in the field of diagnostics, for example. Encouraged by the rapidly increasing demand, many new diagnostics companies have sprouted up in China, all of them eager to claim a share of China’s domestic market and exports.
“The high quality of raw materials is a major sales advantage for Chinese diagnostics companies. It is considered to be a guarantee of quality both on the domestic market and internationally. This explains why we have been so successful in China,” states Råman.
Increasing emphasis on services
Medix Biochemica produces rapid tests that are suitable for monitoring pregnancy and diagnosing acute disease states. The company is currently developing a rapid test reader, which will increase the value of these tests to a significant degree. In the case of borderline results, a reader can provide accurate answers where a visual assessment might lead to false conclusions.
Medix Biochemica intends to further increase the share of services in its business activities. As a result, the company’s product portfolio in the field of bioreagents has diversified. In addition to antibodies, corresponding antigens required for monitoring the quality of the final product have also been made available to Medix Biochemica’s clients.
The development of specifically tailored antibodies with recombinant technology is another new addition to the company’s product portfolio. Medix Biochemica is a true pioneer in this field. Medix Biochemica also offers conjugation services, where antibodies are marked with specific labelling agents needed for concentration measurements.
“We have started calling our business a one-stop IVD shop. It is a fairly good description of the service we provide, since our clients can now get all the raw materials they need for immunoanalytics from us,” concludes Ismo Råman.
Article by FiHTA – Healthtech Finland
This article is a part of Helsinki – cutting-edge life science hub theme that showcases Finland’s life science expertise. Helsinki hosts two major international life science events in September 2013.
